Needham Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $72
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia maintains a 'Buy' rating on Intra-Cellular Therapies (NASDAQ:ITCI) but lowers the price target from $73 to $72.
August 04, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite a lowered price target, Intra-Cellular Therapies maintains a 'Buy' rating from Needham, indicating continued confidence in the stock.
The lowered price target might initially seem negative, but the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100